News | June 08, 2022
ANG Lifesciences India Q4 FY 22 net profit soars to Rs. 5.28 Cr
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
The drug will be manufactured at the group’s topical facility at Ahmedabad
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
The key categories include intimate wellness, skincare & hair care
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Zydus unveils its ‘innovation and care’ centric corporate brand identity
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Subscribe To Our Newsletter & Stay Updated
